Matinas Biopharma (NYSEAMERICAN:MTNB – Get Free Report) announced its earnings results on Friday. The company reported ($0.30) earnings per share (EPS) for the quarter, FiscalAI reports.
Matinas Biopharma Stock Performance
Shares of NYSEAMERICAN MTNB traded down $0.01 during mid-day trading on Friday, reaching $0.64. The company had a trading volume of 16,345 shares, compared to its average volume of 35,569. Matinas Biopharma has a twelve month low of $0.48 and a twelve month high of $3.09. The stock has a market capitalization of $4.09 million, a PE ratio of -0.32 and a beta of 1.61. The stock’s 50 day moving average is $0.58 and its 200-day moving average is $0.75.
Hedge Funds Weigh In On Matinas Biopharma
An institutional investor recently bought a new position in Matinas Biopharma stock. DRW Securities LLC purchased a new position in Matinas Biopharma Holdings, Inc. (NYSEAMERICAN:MTNB – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 46,374 shares of the company’s stock, valued at approximately $27,000. DRW Securities LLC owned about 0.72% of Matinas Biopharma at the end of the most recent quarter. 11.77% of the stock is currently owned by institutional investors.
Matinas Biopharma Company Profile
Matinas Biopharma Inc is a clinical‐stage biopharmaceutical company that specializes in the development of novel lipid‐based drug delivery platforms. Its proprietary Lipid NanoSphere (LNS) technology is designed to encapsulate water‐soluble and hydrophobic therapeutic agents, enabling both oral and intravenous administration. The company’s approach aims to improve drug pharmacokinetics, enhance bioavailability and reduce systemic toxicity compared with conventional formulations.
The lead product candidate, MAT2203, is an oral formulation of amphotericin B being developed for the treatment of cryptococcal meningitis and other life‐threatening fungal infections.
Featured Stories
- Five stocks we like better than Matinas Biopharma
- Excited About Gold But Unsure of Its Trajectory? Try These 3 Approaches
- Dollar at a 3-Year Low: 3 Exporters Quietly Printing Money
- Water Infrastructure: Why This Boring Sector Could Get Exciting
- Harley Pivots Hard: Can New Bikes Fix an Old Brand?
Receive News & Ratings for Matinas Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Matinas Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
